Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
Melody B Oncale, Hossein Maymani, Loretta J Nastoupil Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Abstract: Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma....
Guardado en:
Autores principales: | Oncale MB, Maymani H, Nastoupil LJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0ba68679533d455ca73fb5c9cf5a71ab |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
por: Lapuz C, et al.
Publicado: (2018) -
Uptake of lymphoma-derived exosomes by peripheral blood leukocytes
por: Ferguson Bennit HR, et al.
Publicado: (2017) -
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai C, et al.
Publicado: (2019) -
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
por: Karantanos T, et al.
Publicado: (2017) -
Plasmablastic lymphoma: current perspectives
por: Lopez A, et al.
Publicado: (2018)